Nutra Pharma (Nutra Pharma) COGS-to-Revenue : 0.38 (As of Sep. 2022)

View and export this data going back to . Start your Free Trial

What is Nutra Pharma COGS-to-Revenue?

Nutra Pharma's Cost of Goods Sold for the three months ended in Sep. 2022 was $0.04 Mil. Its Revenue for the three months ended in Sep. 2022 was $0.11 Mil.

Nutra Pharma's COGS to Revenue for the three months ended in Sep. 2022 was 0.38.

Cost of Goods Sold is directly linked to profitability of the company through Gross Margin. Nutra Pharma's Gross Margin % for the three months ended in Sep. 2022 was 62.39%.

Nutra Pharma COGS-to-Revenue Historical Data

The historical data trend for Nutra Pharma's COGS-to-Revenue can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Nutra Pharma COGS-to-Revenue Chart

Nutra Pharma Annual Data

Trend

Dec12

Dec13

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

COGS-to-Revenue

Get a 7-Day Free Trial

0.22

0.89

0.66

0.71

0.92

Nutra Pharma Quarterly Data
	Dec17	Mar18	Jun18	Sep18	Dec18	Mar19	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22
COGS-to-Revenue	Get a 7-Day Free Trial															0.47	2.50	0.64	0.67	0.38

Nutra Pharma COGS-to-Revenue Calculation

Nutra Pharma's COGS to Revenue for the fiscal year that ended in Dec. 2021 is calculated as

COGS to Revenue	=	Cost of Goods Sold	/	Revenue
	=	0.09	/	0.098
	=	0.92

Nutra Pharma's COGS to Revenue for the quarter that ended in Sep. 2022 is calculated as

COGS to Revenue	=	Cost of Goods Sold	/	Revenue
	=	0.041	/	0.109
	=	0.38

Nutra Pharma (OTCPK:NPHC) COGS-to-Revenue Explanation

Cost of Goods Sold is directly linked to profitability of the company through Gross Margin.

Nutra Pharma's Gross Margin % for the three months ended in Sep. 2022 is calculated as:

Gross Margin %	=	1	-	COGS to Revenue
	=	1	-	Cost of Goods Sold / Revenue
	=	1	-	0.041 / 0.109
	=	62.39 %

A company that has a moat can usually maintain or even expand their Gross Margin. A company can increase its Gross Margin in two ways. It can increase the prices of the goods it sells and keeps its Cost of Goods Sold unchanged. Or it can keep the sales price unchanged and squeeze its suppliers to reduce the Cost of Goods Sold. Warren Buffett believes businesses with the power to raise prices have moats.

Nutra Pharma COGS-to-Revenue Related Terms

Thank you for viewing the detailed overview of Nutra Pharma's COGS-to-Revenue provided by GuruFocus.com. Please click on the following links to see related term pages.

Nutra Pharma (Nutra Pharma) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Nutra Pharma Corp (OTCPK:NPHC) » Definitions » COGS-to-Revenue

Comparable Companies

Traded in Other Exchanges

N/A

Address

1537 NW 65th Avenue, Plantation, FL, USA, 33313

Website

https://www.nutrapharma.com

Nutra Pharma Corp operates as a biotechnology company specializing in the acquisition, licensing, and commercialization of pharmaceutical products and technologies for the management of neurological disorders, cancer, autoimmune, and infectious diseases. It also develops proprietary therapeutic protein products primarily for the prevention and treatment of viral and neurological diseases, including Multiple Sclerosis (MS), Adrenomyeloneuropathy (AMN), Human Immunodeficiency Virus (HIV), and pain in humans. Some of its drug names are Cobroxin, Nyloxin, RPI-78M, RPI-MN and Pet Pain-Away.

Executives

Rik J Deitsch	officer: Chief Executive Officer	4001 NW 73 WAY, CORAL SPRINGS FL 33065
Dan Oran	director	8411 W OAKLAND PARK BLVD, #201, SUNRISE FL 33351
Bruno Sartori	other: Former CFO	275 COMMERCIAL BLVD, STE 260, FT LAUDERDALE FL 33308
Harold Henry Rumph	director, officer: President - ReceptoPharm	1537 N.W. 65TH AVENUE, PLANTATION FL 33313
David Michael Isserman	officer: Chief Marketing Officer	2776 UNIVERSITY DRIVE, CORAL SPRINGS FL 33065
Garry Pottruck	director	10768 NW 18TH CT, CORAL SPRINGS FL 33071
Paul F Reid	director	9610 NW 24 CT, SUNRISE FL 33322
Michael Doherty	director, officer: Executive Chairman
Tanvir A Khandaker	director	387 PARK AVENUE SOUTH THIRD FLOOR, NEW YORK NY 10016
Stewart Alan Lonky	director	1158 CHAUTAUQUA BLVD., PACIFIC PALISADES CA 90272
Stanley Jack Cherelstein	director	2401 SW MANOR HILL DRIVE, PALM CITY FL 34990
Michael Flax	director, officer: Chief Financial Officer	2499 BANYAN RD, BOCA RATON FL 33432
Mcclelland David C Sr	director	P.O. BOX 263, FINDLEY LAKE NY 14736
Mitchell S Felder	director	PO BOX 1332, HERMITAGE PA 16148
Khalsa Soram Singh Md	director	436 N BEDFORD DR, BEVERLY HILLS CA 90210

Nutra Pharma (Nutra Pharma) Headlines

From GuruFocus

Nutra Pharma Partners with NxGen Brands for Nyloxin® Distribution

By Marketwired Marketwired • 04-19-2018